Literature DB >> 3580122

Fitting intracranial self-stimulation data with growth models.

D Coulombe, E Miliaressis.   

Abstract

Until now, the problem of fitting self-stimulation rate-frequency functions has been dealt with by using linear models applied to the linear portion of the empirical curve. In this article, an alternative procedure is presented, together with three sigmoid growth models that seem to accurately fit rate-frequency data. From any of these models, it is possible to compute the two indices of stimulation efficacy in use in the parametric study of brain stimulation reward (M50 and theta 0), in addition to the inflection point of the curve, which can be used as an alternative to M50. Important relations allowing initial estimation of each parameter are provided, allowing use of computer programs derived from the Gauss-Newton algorithm for nonlinear regression. The considerations relevant to the choice of a nonlinear model are discussed in terms of each efficacy index.

Mesh:

Year:  1987        PMID: 3580122     DOI: 10.1037//0735-7044.101.2.209

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  14 in total

1.  The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors:  Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Int J Neuropsychopharmacol       Date:  2006-08-31       Impact factor: 5.176

Review 2.  Addiction and brain reward and antireward pathways.

Authors:  Eliot L Gardner
Journal:  Adv Psychosom Med       Date:  2011-04-19

Review 3.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

4.  Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine.

Authors:  Vicky Katsidoni; Kalliopi Apazoglou; George Panagis
Journal:  Psychopharmacology (Berl)       Date:  2010-06-25       Impact factor: 4.530

5.  PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats.

Authors:  Amanda E Higley; Krista Spiller; Peter Grundt; Amy Hauck Newman; Stephen W Kiefer; Zheng-Xiong Xi; Eliot L Gardner
Journal:  J Psychopharmacol       Date:  2010-02-08       Impact factor: 4.153

6.  CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat.

Authors:  Styliani Vlachou; George G Nomikos; George Panagis
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

7.  The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats.

Authors:  Krista Spiller; Zheng-Xiong Xi; Xiao-Qing Peng; Amy H Newman; Charles R Ashby; Christian Heidbreder; József Gaál; Eliot L Gardner
Journal:  Psychopharmacology (Berl)       Date:  2007-11-06       Impact factor: 4.530

8.  Neuropharmacological evidence for the role of dopamine in ventral pallidum self-stimulation.

Authors:  G Panagis; C Spyraki
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

9.  Levo-tetrahydropalmatine inhibits cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats.

Authors:  Zheng-Xiong Xi; Zheng Yang; Shi-Jiang Li; Xia Li; Christopher Dillon; Xiao-Qing Peng; Krista Spiller; Eliot L Gardner
Journal:  Neuropharmacology       Date:  2007-08-15       Impact factor: 5.250

10.  The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats.

Authors:  Xiao-Qing Peng; Charles R Ashby; Krista Spiller; Xia Li; Jie Li; Nitza Thomasson; Mark J Millan; Elisabeth Mocaër; Carmen Muńoz; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2009-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.